A retrospective clinical study of crizotinib compared with pemetrexed-based chemotherapy in non small cell lung cancer
Latest Information Update: 16 Jun 2019
Price :
$35 *
At a glance
- Drugs Crizotinib (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 16 Jun 2019 New trial record
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology